Ceryvyn Therapeutics (CYV) -
Event summary combining transcript, slides, and related documents.
Latest events from Ceryvyn Therapeutics
- Repurposing OPT-302 for LAM targets a rare disease market with high unmet need and strong commercial logic.CYV
Corporate presentation - OPT-302 targets LAM with a capital-efficient, stage-gated rare disease strategy and strong leadership.CYVInvestor presentation
- Returned to profitability with A$330.4 million profit after DFA settlement and strategic reset.CYVH2 2026
- Advancing OPT-302 for LAM with robust funding, expert leadership, and a focused rare disease strategy.CYVInvestor update
- Cash reserves at AUD $31.2M, LAM program underway, ASX reinstatement targeted in H1 2026.CYVQ3 2026 TU
- Phase 3 wet AMD trials fully enrolled; cash runway extended through 2025 topline data.CYVH2 2024
- Profit surges on DFA settlement as focus shifts to LAM, with cash reserves funding near-term plans.CYVH1 2026
- Sozinibercept shows superior efficacy in wet AMD and nears pivotal phase III results in 2025.CYVH.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Sozinibercept aims to set a new standard in wet AMD by improving vision outcomes as an add-on therapy.CYVJefferies 2024 Global Healthcare Conference
- Net loss reached US$131.9M as cash runway supports pivotal trials amid funding uncertainty.CYVH1 2025